Literature DB >> 3049166

Contragestion with late luteal administration of RU 486 (Mifepristone).

C Dubois1, A Ulmann, E E Baulieu.   

Abstract

The efficacy and tolerance of RU 486 prescribed as a late luteal contragestive agent have been evaluated in 139 women at risk of pregnancy. They were given 400 or 600 mg of RU 486 once on the day before the expected menses. Among these women, 48 (34.5%) were pregnant (positive plasma beta-human chorionic gonadotropin, [beta-hCG]) at the time of RU 486 intake. Bleeding occurred in all but six women. An ongoing pregnancy after treatment was found in nine cases (failure rate, 9/48, 18.8%), which was subsequently terminated by surgical procedure in all cases. There was no disturbance in the menstrual cycle, and the tolerance was very satisfactory. In conclusion, this method is acceptable for women at risk of pregnancy in whom other usual postcoital contraceptive methods cannot be prescribed.

Entities:  

Keywords:  Abortifacient Agents; Abortion, Drug Induced; Abortion, Induced; Biology; Comparative Studies; Endocrine System; Evaluation; Family Planning; Fertility Control, Postconception; Hormone Antagonists; Hormones; Physiology; Reproductive Control Agents; Research Methodology; Ru-486--side effects; Ru-486--therapeutic use; Studies

Mesh:

Substances:

Year:  1988        PMID: 3049166

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

Review 1.  Mifepristone. Separating fact from fiction.

Authors:  R C Henshaw; A A Templeton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

Review 2.  Medical termination of pregnancy.

Authors:  J Guillebaud
Journal:  BMJ       Date:  1990 Aug 18-25

Review 3.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.